Systems biology methods help develop a better understanding of hepatitis C virus-induced liver injury

Hepatology

Volumn 56, Issue 1, 2012, Pages 1-4

  Singaravelu, Ragunath ^a,b   Nasheri, Neda ^a,b   Sherratt, Allison ^a   Pezacki, John Paul ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; INTERFERON; RIBAVIRIN;

DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER TRANSPLANTATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; REINFECTION; VIRUS LOAD;

FEMALE; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PROTEIN ARRAY ANALYSIS; PROTEOME; TRANSCRIPTIONAL ACTIVATION;

EID: 84863524145     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25727     Document Type: Editorial

References (30)

1. Aderem A, Adkins JN, Ansong C, Galagan J, Kaiser S, Korth MJ, et al. A systems biology approach to infectious disease research: innovating the pathogen-host research paradigm. MBio 2011; 2: e00325-10.
2. Pezacki JP, Singaravelu R, Lyn RK. Host-virus interactions during hepatitis C virus infection: a complex and dynamic molecular biosystem. Mol BioSyst 2010; 6: 1131-1142.
3. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031.
4. Romero-Gomez M, Eslam M, Ruiz A, Maraver M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int 2011; 31: 443-460.
5. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S, et al. Hepatic cell-specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012 [Epub ahead of print].
6. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis c virus infection. Gastroenterology 2010; 139: 1865-1876.
7. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. HEPATOLOGY 2000; 32: 852-858.
8. Carrion JA, Navasa M, Forns X. Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol 2010; 53: 962-970.
9. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42: 448-456.
10. Smith MW, Walters KA, Korth MJ, Fitzgibbon M, Proll S, Thompson JC, et al. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology 2006; 130: 179-187.
11. Diamond DL, Jacobs JM, Paeper B, Proll SC, Gritsenko MA, Carithers RL Jr, et al. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. HEPATOLOGY 2007; 46: 649-657.
12. Mas V, Maluf D, Archer KJ, Potter A, Suh J, Gehrau R, et al. Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation. Liver Transplant 2011; 17: 824-835.
13. Diamond DL, Krasnoselsky AL, Burnum KE, Monroe ME, Webb-Robertson BJ, McDermott JE, et al. Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus mediated liver disease post-transplantation. HEPATOLOGY 2012; 56: 28-37.
14. Rasmussen AL, Tchitchek N, Susnow NJ, Krasnoselsky AL, Diamond DL, Yeh MM, et al. Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients. HEPATOLOGY 2012; 56: 17-27.
15. Karolczak-Bayatti M, Loughney AD, Robson SC, Europe-Finner GN. Epigenetic modulation of the protein kinase A RIIalpha (PRKAR2A) gene by histone deacetylases 1 and 2 in human smooth muscle cells. J Cell Mol Med 2011; 15: 94-108.
16. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. HEPATOLOGY 2008; 48: 1420-1429.
17. Testino G, Sumberaz A, Ansaldi F, Borro P, Leone S, Ancarani AO, et al. Treatment of recurrent hepatitis C (genotype 1) with pegylated interferon alfa-2b and ribavirin combination and maintenance therapy. Hepatogastroenterology 2011; 58: 536-538.
18. Singal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic agents for liver disease. Liver Int 2011; 31: 1432-1448.
19. Rombouts K, Knittel T, Machesky L, Braet F, Wielant A, Hellemans K, et al. Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J Hepatol 2002; 37: 788-796.
20. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012 [Epub ahead of print].
21. Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012 [Epub ahead of print].
22. Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 622-634.
23. Piccoli C, Quarato G, Ripoli M, D'Aprile A, Scrima R, Cela O, et al. HCV infection induces mitochondrial bioenergetic unbalance: causes and effects. Biochim Biophys Acta 2009; 1787: 539-546.
24. Meikle PJ, Christopher MJ. Lipidomics is providing new insight into the metabolic syndrome and its sequelae. Curr Opin Lipidol 2011; 22: 210-215.
25. Cravatt BF, Wright AT, Kozarich JW. Activity-based protein profiling: from enzyme chemistry. Annu Rev Biochem 2008; 77: 383-414.
26. Blais DR, Nasheri N, McKay CS, Legault MC, Pezacki JP. Activity-based protein profiling of host-virus interactions. Trends Biotechnol 2012; 30: 89-99.
27. Blais DR, Lyn RK, Joyce MA, Rouleau Y, Steenbergen R, Barsby N, et al. Activity-based protein profiling identifies a host enzyme, carboxylesterase 1, which is differentially active during hepatitis C virus replication. J Biol Chem 2010; 285: 25602-25612.
28. Peng X, Gralinski L, Armour CD, Ferris MT, Thomas MJ, Proll S, et al. Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signaling. MBio 2010; 1: e00206-10.
29. Rederstorff M, Huttenhofer A. Small non-coding RNAs in disease development and host-pathogen interactions. Curr Opin Mol Ther 2010; 12: 684-694.
30. van der Meer-Janssen YPM, van Galen J, Batenburg JJ, Helms JB. Lipids in host-pathogen interactions: pathogens exploit the complexity of the host cell lipidome. Prog Lipid Res 2010; 49: 1-26.